Annual Cost of Disease-Modifying Alzheimer's Therapy
Placeholder: annual list price of anti-amyloid therapy overview.
- $26.5k: List price/year (Placeholder cost figure)
- Biweekly: Infusion frequency (Placeholder dosing note)
- +$10k+: Add-on costs (Placeholder monitoring add-on)
- Varies: Medicare share (Placeholder coverage note)
Drug pricing placeholder
Placeholder: list price structure and payer negotiation summary.
Placeholder: cost comparison across approved therapies.
Insurance Coverage Determination and Prior Authorization
Placeholder: how payers determine reimbursement eligibility.
- High: Prior auth rate (Placeholder approval friction)
- Conditional: Medicare coverage (Placeholder CED note)
- Variable: Private payer gap (Placeholder variance note)
- Moderate: Appeal success (Placeholder appeals figure)
Coverage gate placeholder
Placeholder: eligibility criteria and registry requirements.
Placeholder: denial and appeal pathway summary.
PET/MRI Monitoring Cost Burden Over Treatment Course
Placeholder: imaging surveillance requirements and cost stacking.
- 4-5: MRI scans/year (Placeholder ARIA monitoring)
- $5k+: PET scan cost (Placeholder amyloid PET cost)
- Significant: Out-of-pocket add (Placeholder burden note)
- Rural gap: Access disparity (Placeholder imaging access)
Monitoring burden placeholder
Placeholder: required scan schedule and safety monitoring.
Placeholder: cumulative cost of surveillance imaging.
Infusion Center Access Barriers and Geographic Distance
Placeholder: distance and capacity limits on infusion access.
- Sparse: Rural centers (Placeholder facility density)
- 50+ mi: Avg travel distance (Placeholder distance figure)
- High: Capacity constraint (Placeholder wait time note)
- Substantial: Transport burden (Placeholder caregiver burden)
Access barrier placeholder
Placeholder: infusion center distribution and travel burden.
Placeholder: caregiver time and transport cost impact.
Health Equity Access Gaps Across Populations
Placeholder: compounded disparities in therapy access by group.
- Low: Underserved uptake (Placeholder equity gap figure)
- Longer: Diagnostic delay (Placeholder diagnosis disparity)
- Limited: Trial representation (Placeholder trial diversity note)
- Compounding: Combined barrier effect (Placeholder cumulative effect)
Equity gap placeholder
Placeholder: cost, coverage, and access barriers compound inequitably.
Placeholder: policy considerations for narrowing access gaps.
Placeholder: key equity insight summarizing combined barrier impact.